(Q33822780)

29 July 2017

1 reference

title

Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations (English)

1 reference

29 July 2017

A L Jackman

1

1 reference

29 July 2017

R Kimbell

series ordinal

2

1 reference

29 July 2017

H E Ford

series ordinal

3

1 reference

29 July 2017

publication date

1 March 1999

1 reference

European Journal of Cancer

29 July 2017

published in

1 reference

29 July 2017

volume

35 Suppl 1

1 reference

29 July 2017

page(s)

S3-8

1 reference

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

'Tomudex' (ZD1694): A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Mature results from three large controlled studies with raltitrexed ('Tomudex').

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Clinical pharmacology of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900041-6

7 January 2021

10.1016/S0959-8049(99)00041-6

Identifiers

DOI

1 reference

29 July 2017

1 reference